Src
Src(Src激酶)
Src (proto-oncogene tyrosine-protein kinase) is a non-receptor protein tyrosine kinase family including 9 members and promotes survival, angiogenesis, proliferation and invasion pathways.
Src 相关产品(101)
- GC10344PP 2 (AG 1879)CAS: 172889-27-9纯度: >98.50%
PP 2 (AG 1879)是一种选择性Src家族激酶抑制剂。PP 2抑制Lck和Fyn的半数抑制浓度(IC 50 )分别为0.004μM和0.005μM。
- GC14807Fingolimod (FTY720) HClCAS: 162359-56-0纯度: >99.50% / >99.00%
芬戈莫德(FTY720)是一种免疫抑制剂,通常用于治疗多发性硬化症,也有抗癌作用,可以作为HDACi(组蛋白脱乙酰酶抑制剂)。
- GA23328Osteogenic Growth Peptide (10-14)CAS: 105250-85-9纯度: >99.50% / >98.00%
Osteogenic Growth Peptide (10-14)是具有活性的成骨生长肽(OGP)的C端截短的五肽片段,是一种Src kinase(Src)抑制剂。
- GC11526N-Acetyl-O-phosphono-Tyr-Glu DipentylamideCAS: 190078-50-3
Phosphopeptide for binding to the src SH2 domain
- GC12145ENMD-2076 L-(+)-Tartaric acidCAS: 1291074-87-7纯度: >98.50%
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂,对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。
- GC12746N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-GluCAS: 159439-02-8
Phosphopeptide ligand for the src SH2 domain
- GC13117Lck InhibitorCAS: 847950-09-8纯度: >98.50%
A selective inhibitor of lymphocyte-specific protein tyrosine kinase
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC10222 | KX2-391 dihydrochloride | 1038395-65-1 | >98.00% | |
A Src kinase inhibitor | ||||
| GC10344 | PP 2 (AG 1879) | 172889-27-9 | >98.50% | |
PP 2 (AG 1879)是一种选择性Src家族激酶抑制剂。PP 2抑制Lck和Fyn的半数抑制浓度(IC 50 )分别为0.004μM和0.005μM。 | ||||
| GC12185 | ZM 306416 | 690206-97-4 | >99.50% | |
A VEGF receptor kinase inhibitor | ||||
| GC13102 | XL228 | 898280-07-4 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC13343 | Bosutinib (SKI-606) | 380843-75-4 | >99.50% | |
An inhibitor of Src and Abl kinases | ||||
| GC14332 | NVP-BHG712 | 940310-85-0 | >99.50% | |
A selective EphB4 kinase inhibitor | ||||
| GC14807 | Fingolimod (FTY720) HCl | 162359-56-0 | >99.50% / >99.00% | |
芬戈莫德(FTY720)是一种免疫抑制剂,通常用于治疗多发性硬化症,也有抗癌作用,可以作为HDACi(组蛋白脱乙酰酶抑制剂)。 | ||||
| GC15197 | Saracatinib (AZD0530) | 379231-04-6 | >99.50% / >99.00% | |
A dual inhibitor of c-Src and Abl | ||||
| GC17990 | PP 1 | 172889-26-8 | >98.50% | |
PP 1是一种新型的高效、选择性Src家族酪氨酸激酶抑制剂,PP 1有效抑制Lck(IC 50 =5nM)和Fyn(IC 50 =6nM)的磷酸化来阻断T细胞受体信号通路。 | ||||
| GA23328 | Osteogenic Growth Peptide (10-14) | 105250-85-9 | >99.50% / >98.00% | |
Osteogenic Growth Peptide (10-14)是具有活性的成骨生长肽(OGP)的C端截短的五肽片段,是一种Src kinase(Src)抑制剂。 | ||||
| GC10048 | MNS | 1485-00-3 | - | |
An inhibitor of Src, Syk, and platelet aggregation | ||||
| GC10775 | MLR 1023 | 41964-07-2 | >99.50% | |
An allosteric Lyn kinase activator | ||||
| GC11003 | PP121 | 1092788-83-4 | >99.00% | |
A potent dual inhibitor of tyrosine and phosphoinositide kinases | ||||
| GC11526 | N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide | 190078-50-3 | - | |
Phosphopeptide for binding to the src SH2 domain | ||||
| GC11622 | TG 100801 | 867331-82-6 | >98.00% | |
TG 100801 是一种前药,可通过在开发过程中的去酯化作用产生 TG 100572,以治疗年龄相关性黄斑变性。 TG 100572 是一种多靶点激酶抑制剂,可抑制受体酪氨酸激酶和 Src 激酶;对于 VEGFR1、VEGFR2、FGFR1、FGFR2、PDGFRβ、Fgr、Fyn、Hck、Lck、Lyn、Src、Yes , 分别。 | ||||
| GC12145 | ENMD-2076 L-(+)-Tartaric acid | 1291074-87-7 | >98.50% | |
ENMD-2076 L-(+)-Tartaric acid 是一种多靶点激酶抑制剂,对 Aurora A、Flt3、KDR/VEGFR2、Flt4/VEGFR3、FGFR1 的 IC50 为 1.86、14、58.2、15.9、92.7、70.8、56.4 nM , FGFR2, Src, PDGFRα, 分别。 | ||||
| GC12172 | 1-Naphthyl PP1 | 221243-82-9 | >98.50% | |
Inhibitor of modified ‘analog-sensitive’ kinases | ||||
| GC12746 | N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu | 159439-02-8 | - | |
Phosphopeptide ligand for the src SH2 domain | ||||
| GC12958 | ER 27319 maleate | 1204480-26-1 | >99.00% | |
Syk激酶的选择性抑制剂 | ||||
| GC13117 | Lck Inhibitor | 847950-09-8 | >98.50% | |
A selective inhibitor of lymphocyte-specific protein tyrosine kinase | ||||
| GC13410 | Masitinib (AB1010) | 790299-79-5 | >99.50% | |
An inhibitor of c-Kit | ||||
| GC13592 | PD173955 | 260415-63-2 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC13600 | WH-4-023 | 837422-57-8 | >98.00% | |
An inhibitor of Lck and Src | ||||
| GC13797 | PP 3 | 5334-30-5 | - | |
A negative control for Src tyrosine kinase inhibitors | ||||
